197 related articles for article (PubMed ID: 34773056)
1. HLA-G gene editing in tumor cell lines as a novel alternative in cancer immunotherapy.
Palma MB; Tronik-Le Roux D; Amín G; Castañeda S; Möbbs AM; Scarafia MA; La Greca A; Daouya M; Poras I; Inda AM; Moro LN; Carosella ED; García MN; Miriuka SG
Sci Rep; 2021 Nov; 11(1):22158. PubMed ID: 34773056
[TBL] [Abstract][Full Text] [Related]
2. HLA-G: A New Immune Checkpoint in Cancer?
Krijgsman D; Roelands J; Hendrickx W; Bedognetti D; Kuppen PJK
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630545
[TBL] [Abstract][Full Text] [Related]
3. Multiple Knockout of Classical HLA Class II β-Chains by CRISPR/Cas9 Genome Editing Driven by a Single Guide RNA.
Crivello P; Ahci M; Maaßen F; Wossidlo N; Arrieta-Bolaños E; Heinold A; Lange V; Falkenburg JHF; Horn PA; Fleischhauer K; Heinrichs S
J Immunol; 2019 Mar; 202(6):1895-1903. PubMed ID: 30700588
[TBL] [Abstract][Full Text] [Related]
4. The immune-checkpoint HLA-G/ILT4 is involved in the regulation of VEGF expression in clear cell renal cell carcinoma.
García M; Palma MB; Verine J; Miriuka S; Inda AM; Errecalde AL; Desgrandchamps F; Carosella ED; Tronik-Le Roux D
BMC Cancer; 2020 Jul; 20(1):624. PubMed ID: 32620162
[TBL] [Abstract][Full Text] [Related]
5. Natural Killer Cell Cytotoxicity Against SKOV3 after HLA-G Downregulation by shRNA.
Nazari N; Farjadian S
Iran J Immunol; 2016 Sep; 13(3):178-85. PubMed ID: 27671509
[TBL] [Abstract][Full Text] [Related]
6. Rescuing lymphocytes from HLA-G immunosuppressive effects mediated by the tumor microenvironment.
Wu D; Kuiaste I; Moreau P; Carosella E; Yotnda P
Oncotarget; 2015 Nov; 6(35):37385-97. PubMed ID: 26460949
[TBL] [Abstract][Full Text] [Related]
7. Cytokine stimulation of the choriocarcinoma cell line JEG-3 leads to alterations in the HLA-G expression profile.
Persson G; Bork JBS; Isgaard C; Larsen TG; Bordoy AM; Bengtsson MS; Hviid TVF
Cell Immunol; 2020 Jun; 352():104110. PubMed ID: 32387976
[TBL] [Abstract][Full Text] [Related]
8. HLA-G and Other Immune Checkpoint Molecules as Targets for Novel Combined Immunotherapies.
Morandi F; Airoldi I
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328349
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Transcriptomic Analysis Reveals the Role of the Immune Checkpoint HLA-G Molecule in Cancers.
Xu HH; Gan J; Xu DP; Li L; Yan WH
Front Immunol; 2021; 12():614773. PubMed ID: 34276642
[TBL] [Abstract][Full Text] [Related]
10. Gene Editing in B-Lymphoma Cell Lines Using CRISPR/Cas9 Technology.
Bai B; Myklebust JH; Wälchli S
Methods Mol Biol; 2020; 2115():445-454. PubMed ID: 32006416
[TBL] [Abstract][Full Text] [Related]
11. Utilizing CRISPR/Cas9 technology to prepare lymphoblastoid cell lines harboring genetic mutations for generating quality control materials in genetic testing.
Zhou L; Li R; Zhang R; Peng R; Chen K; Gao P; Zhang J; Zhang R; Li J
J Clin Lab Anal; 2020 Jul; 34(7):e23256. PubMed ID: 32118319
[TBL] [Abstract][Full Text] [Related]
12. Design of a generic CRISPR-Cas9 approach using the same sgRNA to perform gene editing at distinct loci.
Najah S; Saulnier C; Pernodet JL; Bury-Moné S
BMC Biotechnol; 2019 Mar; 19(1):18. PubMed ID: 30894153
[TBL] [Abstract][Full Text] [Related]
13. CD8
Dumont C; Jacquier A; Verine J; Noel F; Goujon A; Wu CL; Hung TM; Desgrandchamps F; Culine S; Carosella ED; Rouas-Freiss N; LeMaoult J
Cancer Immunol Res; 2019 Oct; 7(10):1619-1632. PubMed ID: 31451484
[TBL] [Abstract][Full Text] [Related]
14. Tumor infiltrating and peripheral CD4
Jacquier A; Lambert T; Delattre JF; Djouadou M; Vérine J; Dumont C; Desgrandchamps F; Carosella ED; LeMaoult J; Rouas-Freiss N
Cancer Lett; 2021 Oct; 519():105-116. PubMed ID: 34186161
[TBL] [Abstract][Full Text] [Related]
15. The dual role of HLA-G in cancer.
Rouas-Freiss N; Moreau P; LeMaoult J; Carosella ED
J Immunol Res; 2014; 2014():359748. PubMed ID: 24800261
[TBL] [Abstract][Full Text] [Related]
16. The choriocarcinoma cell line JEG-3 upregulates regulatory T cell phenotypes and modulates pro-inflammatory cytokines through HLA-G.
Melsted WN; Matzen SH; Andersen MH; Hviid TVF
Cell Immunol; 2018 Feb; 324():14-23. PubMed ID: 29198970
[TBL] [Abstract][Full Text] [Related]
17. Construction of an Inducible CRISPR/Cas9 System for CXCR4 Gene and Demonstration of its Effects on MKN-45 Cells.
Peng Y; Yang T; Tang X; Chen F; Wang S
Cell Biochem Biophys; 2020 Mar; 78(1):23-30. PubMed ID: 31875277
[TBL] [Abstract][Full Text] [Related]
18. Integrate CRISPR/Cas9 for protein expression of HLA-B*38:68Q via precise gene editing.
Yin Y; Reed EF; Zhang Q
Sci Rep; 2019 May; 9(1):8067. PubMed ID: 31147565
[TBL] [Abstract][Full Text] [Related]
19. Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.
Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Al Abdulmonem W; Moawad AA; Alwanian WM; Almansour NM; Rahmani AH; Khan AA
Int J Nanomedicine; 2023; 18():5531-5559. PubMed ID: 37795042
[TBL] [Abstract][Full Text] [Related]
20. Genetic reprogramming for NK cell cancer immunotherapy with CRISPR/Cas9.
Afolabi LO; Adeshakin AO; Sani MM; Bi J; Wan X
Immunology; 2019 Oct; 158(2):63-69. PubMed ID: 31315144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
